M&A Activities, Pending NDA Approvals, and Clinical Trial Results - Research Report on Sanofi, GSK, AstraZeneca, Keryx, and

 M&A Activities, Pending NDA Approvals, and Clinical Trial Results - Research
             Report on Sanofi, GSK, AstraZeneca, Keryx, and Rigel

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 29, 2013

NEW YORK, August 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Sanofi SA
(NYSE: SNY), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN),
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), and Rigel Pharmaceuticals, Inc.
(NASDAQ: RIGL). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Sanofi SA Research Report

On August 26, 2013, Sanofi SA (Sanofi) announced that its vaccine division,
Sanofi Pasteur, has released topline results of a large-scale, multi-center
efficacy trial in people aged 65 years and above, showing a superior clinical
benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the
standard dose of Fluzone vaccine in preventing influenza. The Company informed
that further data analyses of secondary endpoints are ongoing. Sanofi Pasteur
expects to submit the full clinical study report to the US Food and Drug
Administration (FDA) for review by early 2014, and will seek a modification to
the label for Fluzone High-Dose vaccine. The Full Research Report on Sanofi SA
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/29ea_SNY]

--

GlaxoSmithKline plc Research Report

On August 23, 2013, GlaxoSmithKline plc (GSK) announced that the first of the
four Phase III studies, the SHIELD-1 study, that investigated vercirnon in
adult patients with moderately-to-severely active Crohn's disease failed to
achieve the primary endpoint of improvement in clinical response and the key
secondary endpoint of clinical remission. The Company informed that new
recruitment and dosing in the ongoing clinical program has been suspended
pending further review of the SHIELD-1 results. GSK also informed that
vercirnon is not approved or licensed for use anywhere globally. The Full
Research Report on GlaxoSmithKline plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]

--

AstraZeneca PLC Research Report

On August 26, 2013, AstraZeneca PLC announced that its global biologics
research and development arm, MedImmune, has entered into a definitive
agreement to acquire Amplimmune, a privately-held biologics company focused on
developing novel therapeutics in cancer immunology. Under the terms of the
agreement, MedImmune will acquire 100% of Amplimmune's shares for an initial
consideration of $225 million and deferred consideration of up to $275
million, based on reaching predetermined development milestones. Dr. Bahija
Jallal, Executive Vice President of MedImmune, stated, "MedImmune's focus on
harnessing the power of the patient's own immune system to fight cancer will
be complemented by Amplimmune's innovative work in this area." Bahija Jallal
added, "It will allow us to strengthen our arsenal of potential cancer
therapies." The Companies expect the proposed transaction to close in Q3 2013.
The Full Research Report on AstraZeneca PLC - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]

--

Keryx Biopharmaceuticals, Inc. Research Report

On August 8, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced that it
has submitted a New Drug Application (NDA) to the FDA seeking approval for the
marketing and sale of Zerenex, the Company's drug candidate for the treatment
of elevated serum phosphorus levels, or hyperphosphatemia, in patients with
chronic kidney disease (CKD) on dialysis. Ron Bentsur, CEO of Keryx, stated,
"With approximately 1,500 patients exposed to the drug in the clinical
development programs conducted by us and our Japanese partner, JT/Torii, we
believe that Zerenex is a safe, effective and highly-differentiated drug
candidate and today's submission brings us one step closer to potentially
bringing this drug to patients who can benefit from it." The Company also
stated that it intends to submit a Marketing Authorization Application (MAA)
to the European Medicines Agency (EMA) for regulatory approval of Zerenex in
the European Union. The Full Research Report on Keryx Biopharmaceuticals, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/27d2_KERX]

--

Rigel Pharmaceuticals, Inc. Research Report

On August 26, 2013, Rigel Pharmaceuticals, Inc. (Rigel) announced that R343,
an inhaled SYK inhibitor being assessed as a potential therapeutic for
patients with allergic asthma, did not meet the primary or secondary endpoints
in a recently completed Phase 2 clinical study. Consequently, the Company has
decided not to pursue the indication with R343. James M. Gower, Chairman and
CEO of Rigel, stated, "This was not the result we expected based on the
collection of data we had previously seen with R343 in this therapeutic area."
The Full Research Report on Rigel Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c8b0_RIGL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)